The UK Medicines and Healthcare Regulatory Agency (MHRA) has approved GenSight Biologics’ clinical trial application (CTA) to initiate the Phase I/II trial of GS030 to treat patients with retinitis pigmentosa (RP).

PIONEER will examine the safety and tolerability of GS030 in RP patients as part of a multi-centre, open-label dose-escalation study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It expects to enrol patients affected by end-stage non-syndromic RP with vision not better than ‘counting fingers’.

The trial will include three groups of three subjects, which will each receive an increasing dose of GS030-DP through a single intravitreal injection in their worse affected eye.

A fourth extension cohort is also expected to receive the highest tolerated dose.

“For the first time ever in ophthalmology, an optogenetic approach combined with a medical device will be tested in humans.”

PIONEER will also include an independent data safety monitoring board (DSMB) that will review safety information of all treated subjects in each group and make recommendations before proceeding to the next higher dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary objective will be the safety and tolerability at one-year post-injection, with the first patient expected to be treated in the UK during the first quarter of this year.

GenSight Biologics CEO and co-founder Bernard Gilly said: “For the first time ever in ophthalmology, an optogenetic approach combined with a medical device will be tested in humans.

“If proven safe and effective, this therapy could be transferable from Retinitis Pigmentosa to dry-AMD.”

GenSight’s GS030 is a combination of a gene therapy (GS030-DP) designed to be administered through a single intravitreal injection and a wearable optronic visual stimulation device (GS030-MD).

The solution has already received orphan drug designation in the US and Europe.